Literature DB >> 10715685

The Thai-Burmese border: drug studies of Plasmodium falciparum in pregnancy.

R McGready1, F Nosten.   

Abstract

Plasmodium falciparum malaria is increasing world-wide, as is resistance to the available antimalarials. On the Thai-Burmese border this problem is most acute in pregnant women, as options for their treatment are even more restricted because of the unknown effects of antimalarials on the foetus. Presented here are the results of descriptive, clinical, drug studies on quinine, mefloquine and artemisinin derivatives for P. falciparum in pregnant women. Mefloquine and quinine have high failure rates for primary and recrudescent infections. Artemisinin-based treatments in pregnant women have proved safe, tolerable and efficacious. However, randomized drug studies with these drugs and other new antimalarials are required to define the true safety and efficacy of these drugs in pregnant women.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10715685     DOI: 10.1080/00034989957709

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  10 in total

1.  Field evaluation of a novel colorimetric method--double-site enzyme-linked lactate dehydrogenase immunodetection assay--to determine drug susceptibilities of Plasmodium falciparum clinical isolates from northwestern Thailand.

Authors:  Alan Brockman; Sittaporn Singlam; Lucy Phiaphun; Sornchai Looareesuwan; Nicholas J White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand.

Authors:  Anne-Catrin Uhlemann; Rose McGready; Elizabeth A Ashley; Alan Brockman; Pratap Singhasivanon; Sanjeev Krishna; Nicholas J White; Francois Nosten; Ric N Price
Journal:  J Infect Dis       Date:  2006-11-21       Impact factor: 5.226

Review 3.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria.

Authors:  R McGready; K Stepniewska; S A Ward; T Cho; G Gilveray; S Looareesuwan; N J White; F Nosten
Journal:  Eur J Clin Pharmacol       Date:  2006-03-22       Impact factor: 2.953

Review 5.  A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy.

Authors:  Christine Manyando; Kassoum Kayentao; Umberto D'Alessandro; Henrietta U Okafor; Elizabeth Juma; Kamal Hamed
Journal:  Malar J       Date:  2012-05-01       Impact factor: 2.979

6.  Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study.

Authors:  R McGready; S J Lee; J Wiladphaingern; E A Ashley; M J Rijken; M Boel; J A Simpson; M K Paw; M Pimanpanarak; Oh Mu; P Singhasivanon; N J White; F H Nosten
Journal:  Lancet Infect Dis       Date:  2011-12-12       Impact factor: 25.071

Review 7.  The safety of artemisinins during pregnancy: a pressing question.

Authors:  Stephanie Dellicour; Susan Hall; Daniel Chandramohan; Brian Greenwood
Journal:  Malar J       Date:  2007-02-14       Impact factor: 2.979

Review 8.  Intermittent presumptive treatment for malaria.

Authors:  Nicholas J White
Journal:  PLoS Med       Date:  2005-01       Impact factor: 11.069

Review 9.  Treating severe malaria in pregnancy: a review of the evidence.

Authors:  Stephanie D Kovacs; Marcus J Rijken; Andy Stergachis
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

10.  The Safety of Artemisinin Derivatives for the Treatment of Malaria in the 2nd or 3rd Trimester of Pregnancy: A Systematic Review and Meta-Analysis.

Authors:  Stephanie D Kovacs; Anna Maria van Eijk; Esperanca Sevene; Stephanie Dellicour; Noel S Weiss; Scott Emerson; Richard Steketee; Feiko O Ter Kuile; Andy Stergachis
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.